innovationmap awards

Houston founders share the challenges they've had to overcome as women in tech

The five finalists in the Female-Founded Business category for the inaugural InnovationMap Awards share the challenges they overcame as female founders. Photos courtesy

Even in 2021, women face discrimination in the workplace — whether it's running their own businesses or climbing the corporate ladder.

The five female finalists of the Female-Founded Business category for the InnovationMap Awards presented by Techwave were asked to share their challenges overcame as female founders. Here's what they had to say. Click here to register for the livestream.

Raising capital

Carolyn Rodz, founder of Hello Alice, says raising capital was her biggest challenge.

"We overcame it through insane networking and persistence," she continues. "Each round got easier as we proved that we knew how to grow this business and build a fiercely loyal owner community.

Katharine Forth, co-founder of Zibrio, agrees that raising early funding was her biggest challenge.

"To overcome it, I was very creative with the limited funds to generate the progress we created until we reached a threshold that was more comfortable for investors," she explains.

Being the only woman in the room

"This is a hurdle in and of itself, but it brings lots of other little behavioral hurdles too," says Kim Raath, CEO and co-founder of Topl. "Because men and women are socialized so differently, women often have to adapt to or accommodate for male-pattern behaviors."

Raath continues, saying how men tend to up-sell what they are doing, while women undersell. Additionally, she says, men are more likely to make statements while women suggest their ideas.

"It takes a lot of courage to fight for yourself and your ideas in a room full of men," Raath says. "You can't expect others to do it for you. Even further, those of us that are in the room have a duty to speak up, not just for our own sake, but for other voices that are still excluded. Being a woman in the tech space means learning how to accommodate, navigate, and hold your ground."

Being treated equally

For Samantha Snabes, co-founder of re:3D, her biggest challenge was being treated the same as her male co-founder.

"I've learned that I need to be more confident and to be proud of the differences in my leadership or communication style," she explains.

Being mistaken for the secretary

Shoshi Kaganovsky, founder of RingOn, says electronics is a very male dominated arena.

"Every time I approach a man — whether to interview him for a job or to partner up on another level — they think I'm the CEO's secretary," she says.

"When male investors talk to me they often times think I don't understand what I'm doing or that they need to dumb it down for me," continues Kaganovsky, who speaks five languages and has six degrees. "Second conversations are completely different usually."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted